Abbvie Reports First Provincial Reimbursements for VENCLEXTA in Combination with Azacitidine for Acute Myeloid Leukemia Patients | Financial Buzz

Abbvie Reports First Provincial Reimbursements for VENCLEXTA in Combination with Azacitidine for Acute Myeloid Leukemia Patients

AbbVie (NYSE: ABBV) has reported an agreement with the pan-Canadian Pharmaceutical Alliance for VENCLEXTA in combination with azacytidine for treatment of patients that are diagnosed with acute myeloid leukemia that are 75 years or older or individuals who have comorbidities that preclude use of intensive induction chemotherapy.  “Acute myeloid leukemia is a blood cancer with a survival rate that still needs to be improved. Intensive chemotherapy treatments lead to toxicity, which can limit their use. However, our understanding of this disease has improved considerably over the past few years and, thanks to new treatment options such as the combination of venetoclax and azacitidine, we are now able to effectively treat a greater proportion of patients,” explains Dr. Julie Bergeron, MD, FRCPC, associate clinical professor, head of the Optilab CHUM cluster of hematology laboratories, and hematologist at the CEMTL Maisonneuve-Rosemont facility.

“Every day, we aim to transform the standard of care in Oncology. Having effective and proven treatment options is vital for patients and their families impacted by AML. It is great news that VENCLEXTA plus azacitidine is now reimbursed in Quebec, Saskatchewan and Manitoba for people living with AML,” says Tracey Ramsay, Vice President and General Manager, AbbVie Canada.

Opt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!